疫苗前沿 | 一项诺如病毒候选疫苗临床试验背后的思考

疫苗前沿 | 一项诺如病毒候选疫苗临床试验背后的思考
2025年05月28日 09:02 记经典时刻

来源:生命科学前沿

图片来源:

Vaxart公司官网

参考资料:

Flitter BA, Greco SN, Lester CA, et al. An oral norovirus vaccine tablet was safe and elicited mucosal immunity in older adults in a phase 1b clinical trial. Science Translational Medicine. 2025;17(788):eads0556. doi:10.1126/scitranslmed.ads0556

Kim L, Liebowitz D, Lin K, et al. Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial. JCI Insight. 2018;3(13):e121077, 121077. doi:10.1172/jci.insight.121077

Positive topline data from Phase II trial of Vaxart’s norovirus vaccine pill. Accessed May 1, 2025. https://www.clinicaltrialsarena.com/news/positive-topline-vaxart-norovirus-vaccine-pill/

This Week in Virology (TWiV) Episode 1209, https://www.microbe.tv/twiv/twiv-1209/

Vaxart. Vaxart, Inc. –Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate. Vaxart. April 30, 2025. Accessed May 1, 2025. https://investors.vaxart.com/news-releases/news-release-details/vaxart-completes-enrollment-phase-1-trial-its-norovirus-oral

来源:预防界

财经自媒体联盟更多自媒体作者

新浪首页 语音播报 相关新闻 返回顶部